Navigation Links
RxTrials Announces Hiring Adam Chasse as VP of Business Development
Date:5/11/2011

ELLICOTT CITY, Md., May 11, 2011 /PRNewswire/ -- Christine Pierre, president of RxTrials, Inc., today named Adam Chasse vice president of business development. Chasse, who has been head of prime sites for Quintiles, will begin on May 11 and be based in Triangle Park, North Carolina.

"I have collaborated with Adam for 16 years and have admired what he has accomplished personally and for his employer, but what really stands out for me is his integrity. Yes, he brings a global perspective and valuable experience gained by working for the largest contract research organization in the world, but, more importantly, he brings a vision for the future of our organization that is closely aligned with that of our other top managers," said Pierre.

Chasse has served on the board of advisors for the Site Solutions Summit since its inception seven years ago. The Summit is an annual industry meeting organized by RxTrials Institute and focused on research sites' best practices. RxTrials Institute is an RxTrials affiliate.

"Quite frankly he was my first choice; I've been asking him for about five years when he was going to come to the other side and join the sites world," said Pierre with a smile.

"I'm very, very excited because I've always admired RxTrials for its history of delivery and quality, and its forward-thinking approach to improving research practices," said Chasse.

Chasse and Pierre agree that it is becoming increasingly difficult for independent research practices to leverage the economies of scale necessary to be successful. A network of research sites, they say, provides ways to keep sites busier and guarantee high-quality end results while assuring positive patient experiences.

RxTrials has eight research sites located in five states, all of which are located within clinical practices or hospitals.  "Adam will provide RxTrials with strategic site development and study placement opportunities focused on our clients' needs," said Pierre.

"RxTrials' vision for expanding opportunities for patients and physicians to take part in important research is identical to mine, so I feel we're a perfect fit," said Chasse.

"It's so expensive to take a drug through the research process, which has been further complicated by the fact that pharma companies are looking at rarer diseases than they were 10 years ago. Therefore, it's more difficult to run a trial in the same period of time partly because it's harder to find enough patients," said Chasse. "On top of that, study designs are getting more complex and investigators are being challenged to recruit more patients while adding procedures and tests. Plus, there is more scrutiny of data by Sponsors and FDA."

"What Sponsors and physicians need is an entity that can help them navigate that process," added Pierre.

"Christine is an innovator and recognized leader in the industry. She has the respect of everyone who knows her. Hers is one of the very few site networks that emerged since 1990 that is still not only around but thriving," said Chasse.

"The deal was recently closed and not yet publically announced and I've already fielded calls from colleagues in the industry. It seems good news travels fast," said Pierre.

About RxTrials, Inc.

RxTrials is a network of premier Investigative Sites based in physician practices and hospitals that conduct Phase II through Phase IV and vaccine clinical research studies. Since 1994, RxTrials has successfully completed more than 1,000 studies and is a strategic partner with leading Sponsors and CROs.  Its affiliate, RxTrials Institute, provides professional training, education and consultation, and sponsors the annual Site Solutions Summit.

Interviews and print-quality images of the logo and personnel are available upon request.


'/>"/>
SOURCE RxTrials, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RxTrials Earns National Women-Owned Business Certification
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic Information for ... Discovery --> --> The ... sequence 100,000 individuals. It is intended to initially include populations ... North and East Asian countries. --> ... focus on creating phased reference genomes for all major Asian ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit ... are researched, developed, marketed and made accessible to patients around ... Open had named the publication of the Good ... The publication is also featured as one of BMJ ... the last year that are most frequently read. ...
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) to distribute exosome injection and other biological products ... Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, ...
Breaking Biology Technology:
(Date:2/9/2016)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2015.  ... 2015 was $6.9 million, an increase of 61% compared to $4.3 ... fourth quarter of 2015 was $2.6 million compared to $0.2 million ... --> Higher revenue and operating income in the ...
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):